Table 1.
Characteristics of patients treated before or after CDI guideline publication
| Variable | Before guidelines (N = 293) | After guidelines (N = 728) | P value |
|---|---|---|---|
| Age (mean ± s.d.) | 64·3 ± 16·8 | 61·9 ± 18·5 | 0·052 |
| Gender | 0·347 | ||
| Male, n (%) | 152 (52%) | 354 (49%) | |
| Service | 0·409 | ||
| Medicine, n (%) | 237 (81%) | 572 (79%) | |
| Surgery, n (%) | 56 (19%) | 156 (21%) | |
| IBD | |||
| Crohn's, n (%) | 8 (3%) | 27 (4%) | 0·437 |
| UC, n (%) | 6 (2%) | 24 (3%) | 0·285 |
| Chemotherapy, n (%) | 63 (22%) | 155 (21%) | 0·941 |
| Radiation, n (%) | 22 (8%) | 51 (7%) | 0·778 |
| LOS (mean ± s.d.) | 11·9 ± 13 | 12·7 ± 14 | 0·458 |
| ICU | 0·02 | ||
| IMC, n (%) | 99 (34%) | 232 (32%) | |
| ICU, n (%) | 41 (14%) | 172 (24%) | |
| Discharge | <0·0001 | ||
| To home, n (%) | 226 (77%) | 436 (60%) | |
| To rehab/facility, n (%) | 39 (13%) | 292 (40%) | |
| Disease severity | 0·248 | ||
| Mild–moderate, n (%) | 208 (71%) | 558 (76%) | |
| Severe, n (%) | 37 (13%) | 79 (11%) | |
| Severe-complicated, n (%) | 48 (16%) | 144 (14%) | |
| Steroids, n (%) | 73 (25%) | 214 (29%) | 0·15 |
| Medication usage | |||
| Metronidazole, n (%) | 258 (88%) | 668 (92%) | 0·065 |
| Vancomycin oral, n (%) | 133 (45%) | 370 (51%) | 0·116 |
| Vancomycin enema, n (%) | 0 (0%) | 32 (4·4%) | 0·001 |